No abstract

Haloperidol, olanzapine and risperidone are superior to aripiprazole, quetiapine and ziprasidone for the acute treatment of psychosis in hospitalised patients with schizophrenia, schizoaffective disorder or schizophreniform disorder.

To the Editor: The problem of increased obesity in the US population is magnified among patients with major psychiatric disorders, whose rates of obesity are multiples of the general population's. 1 Many psychotropic medications, particularly some second-generation antipsychotics, are associated with weight gain. However, molindone is a first-generation antipsychotic of the dihydroindolone class with a package insert 2 stating that changes in weight are in the direction of normal or ideal weight and that excessive weight gain has not occurred. In fact, it has been shown to lead to weight loss. 3 While this property would seem to recommend its use in light of present-day concerns about obesity and the metabolic syndrome, molindone has not been well studied 4 and has a very small market share. 5 We have found that more recently trained psychiatrists are completely unfamiliar with the drug, while those trained before the development of second-generation antipsychotics have vague memories of its being questionably effective. In a move toward reintroducing this drug into our practice, we treated 3 adult patients with both morbid obesity and a psychotic disorder with molindone. All experienced both an improvement in mental status and weight loss. We present the 3 cases here. Case 1. Mr A is a 51-year-old man with a history of DSM-IV paranoid schizophrenia, alcohol abuse, obesity, and hypertension who was admitted to our hospital in November 2008. Presenting problems were grandiose and persecutory delusions, auditory hallucinations, tangential thought processes, and irritability. Mr A's Brief Psychiatric Rating Scale (BPRS) 6 score on admission was 43. His weight on admission was 326.9 lb, and his body mass index

No abstract

Aim: To determine the association between presenting for antenatal check-up Methods: Study conducted in the Department of Obstetrics & Gynecology, Lahore General Hospital of Lahore during 15-5-2019 to 15-11-2019 and consented to participate were considered for the study. 35 were with preeclampsia (Cases) and 35 were without (Control). The data was entered and analyzed using SPSS 25. For categorical data analysis chi square test was used using p-value ≤0.05. 70 Women of age 18-40years, parity of 20 weeks (on LMP) Results: The study results showed that the mean age of the cases group was 29.54±6.284 years whereas the mean age of control group was 28.83±7.213 years. In the present study among cases the low platelets count was noted in 26(74.3%) patients while among control group the low platelets count was found in 17(48.6%) patients. Odds of developing preeclampsia among patients aged below or equals to 30 years was 3.97 [95% CI: 0.95-16.52] whereas among aged >30, was 3.06 [95% CI: 0.68-13.78]. The odds of developing preeclampsia among low platelet count subjects with normal BMI was 3.50 [95% CI; 0.69-17.71] Conclusion: Low platelets count was associated with preeclampsia. It was found that pregnant females with low platelet count has significantly greater odds of developing preeclampsia as compared to normal platelets count females presenting during third trimester of pregnancy. Keywords: Pregnant Female, Low platelet count, Preeclampsia, Pregnancy, Case Control Study